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Abstract
Background: Acetyl Coenzyme A carboxylase b (ACACB) is the rate-limiting enzyme in fatty acid oxidation, and continuous
fatty acid oxidation in Acacb knock-out mice increases insulin sensitivity. Systematic human studies have not been
performed to evaluate whether ACACB variants regulate gene expression and insulin sensitivity in skeletal muscle and
adipose tissues. We sought to determine whether ACACB transcribed variants were associated with ACACB gene expression
and insulin sensitivity in non-diabetic African American (AA) and European American (EA) adults.
Methods: ACACB transcribed single nucleotide polymorphisms (SNPs) were genotyped in 105 EAs and 46 AAs whose body
mass index (BMI), lipid profiles and ACACB gene expression in subcutaneous adipose and skeletal muscle had been
measured. Allelic expression imbalance (AEI) was assessed in lymphoblast cell lines from heterozygous subjects in an
additional EA sample (n=95). Selected SNPs were further examined for association with insulin sensitivity in a cohort of 417
EAs and 153 AAs.
Results: ACACB transcribed SNP rs2075260 (A/G) was associated with adipose ACACB messenger RNA expression in EAs and
AAs (p=3.8610
25, dominant model in meta-analysis, Stouffer method), with the (A) allele representing lower gene
expression in adipose and higher insulin sensitivity in EAs (p=0.04). In EAs, adipose ACACB expression was negatively
associated with age and sex-adjusted BMI (r=20.35, p=0.0002).
Conclusions: Common variants within the ACACB locus appear to regulate adipose gene expression in humans. Body fat
(represented by BMI) may further regulate adipose ACACB gene expression in the EA population.
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Introduction
Acetyl-CoA carboxylase a and b (ACC1/ACACA and ACC2/
ACACB) catalyze the synthesis of malonyl-CoA, the substrate for
fatty acid synthesis and a regulator of fatty acid oxidation.
Increased malonyl-CoA concentrations inhibit carnitine palmi-
toyaltransferase-1 (CPT1) activity, decreasing the rate of fatty
acid entry into mitochondria and subsequent fatty acid oxidation
[1]. ACACB is the key regulator of the fatty acid oxidation
pathway [2] and Acacb knock-out mice are reportedly protected
against obesity and diabetes induced by high fat/high carbohy-
drate diets [3]. Continuous fatty acid oxidation in adipocytes of
Acacb knock-out mice is one factor contributing to their high
insulin sensitivity [4]. Human gene expression studies suggest that
ACACB is abundantly expressed in both oxidative and lipogenic
tissues [5,6].
When dietary intake exceeds the storage capacity of adipose
tissue, excess lipid is delivered as ectopic fat to skeletal muscle,
liver, pancreatic b-cells, and cardiac muscle. The resulting organ
dysfunction, known as ‘‘lipotoxicity’’, results in impaired insulin
action and glucose homeostasis, and ultimately type 2 diabetes;
however, the cellular mechanisms and intermediates are not fully
understood [7–11]. Acacb knock-out mice [2,3,4] and rats treated
with Acaca or Acacb anti-sense nucleotide inhibitors [12] suggested
a potential therapeutic target for ACACB in insulin resistance,
obesity, metabolic syndrome, and type 2 diabetes. Alternations in
nutritional status may also regulate ACACA and ACACB
expression [13,14].
ACACB single nucleotide polymorphism (SNP) rs4766587
[15,16] is associated with an increased risk of metabolic syndrome.
Interestingly, a common SNP rs2268388 within ACACB is
reproducibly associated with type 2 diabetes-related proteinuria
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populations [6,17]. Animal studies [3] suggest that the lack of
strong association between ACACB variants and obesity/diabetes
may be masked by the cross-regulation of ACACB expression and
hormonal/nutritional status in insulin-sensitive tissues [18,19].
Gene-nutrient interactions may further influence the expression of
functional variants in ACACB and their relationships with insulin
sensitivity [16]. The ACACB cis regulatory SNPs rs2075259 and
rs2075263 were significantly associated with ACACB messenger
RNA levels in skeletal muscle (p=3.0610
28 and p=5.2610
27,
respectively) [20].
We hypothesized that: (a) cis SNPs may regulate ACACB
expression in insulin sensitive tissues and by consequence affect
insulin sensitivity, and (b) body fat, represented by body mass
index (BMI), may regulate ACACB expression in insulin responsive
tissues. Therefore, we investigated the association between
transcribed SNPs in ACACB and subcutaneous adipose tissue
and skeletal muscle ACACB gene expression, as well as insulin
sensitivity in European Americans (EAs) and AAs. We also tested
for relationships between BMI and ACACB messenger RNA
expression in adipose and skeletal muscle tissues.
Results
Demographic characteristics of study subjects are listed in
Table 1.
ACACB transcribed SNPs are associated with adipose
ACACB messenger RNA expression
Eleven ACACB SNPs were genotyped in 105 EA and 46 AA
subjects who were non-diabetic at the time of adipose and skeletal
muscle biopsies. The linkage disequilibrium (LD) plots are shown
in Figure 1. The LD pattern in EAs was similar to HapMap
Caucasians, but differed from AAs and HapMap Yoruba Africans
(Figure S1). The patterns of ACACB LD in AAs reflected those
reported in HapMap for Yoruba Africans, with the exceptions of
rs2075260 and rs2075263 for which the observed level was
midway between HapMap Caucasians and Yoruba.
In subcutaneous adipose tissue, SNPs rs7135947, rs2075259,
rs2075260, and rs2075263 were nominally associated with ACACB
messenger RNA levels from the combined sample of EAs and AAs,
after adjusting for age, sex, BMI, and race (p=0.02-0.05, additive
model; Table 2). The association of rs2075260 with ACACB
expression was seen in EAs and AAs with the same direction of
effect (p=0.0007 and 0.01 respectively after adjusting for age, sex,
and BMI; dominant model) (Table 2). When combining the
association p-values in the two races by meta-analysis, the best p-
value for association of rs2075260 with ACACB gene expression
reached 5.5610
25 (dominant model, Fisher’s method) and
3.8610
25 (dominant model, Stouffer’s method) (Figure. 2). SNP
rs7135947 was nominally associated with ACACB expression in
AAs after adjusting for age, sex, and BMI (p=0.04, additive
model; Table 2). The association was not statistically significant in
EAs, although the trend of expression versus genotype was
consistent (Table 2). Since rs2075260 and rs7135947 are not in
LD (r
2#1 in both EAs and AAs), when accounting for the additive
effect of the eQTL-increasing alleles (G for rs2075260 and C for
7135947), the adjusted ACACB expression level was positively
associated with the sum of eQTL-increasing alleles in AAs
(p=0.0046), as well as in EA and AA combined biopsy sample
(p=0.0001), but not in EAs alone (p=0.11) (Figure S2; adjusted
ACACB expression levels were controlled for age, sex, BMI, and
ethnicity). Association between rs3742023 and ACACB expression
was present in AAs, but not EAs (Table 2).
In skeletal muscle, rs2075260 and rs2075263 were nominally
associated with ACACB messenger RNA levels in AAs, after
adjusting for age, sex, and BMI (p=0.03-0.003; additive and
dominant/recessive models). However, association was not
replicated in EAs and no evidence of association was observed
in the combined biopsy sample for any of the tested SNPs
(Table 2).
Allelic expression imbalance of ACACB transcribed SNPs
in lymphoblast cell lines
To identify a potential regulatory effect of ACACB transcribed
SNPs, we applied an independent method to test AEI for six of the
eight coding variants in lymphoblast cell lines from 95 Utah EAs
under controlled cell culture conditions. In this group, 18 subjects
were heterozygous for rs2075260 (A/G), where the mean (6 SE)
normalized percentage of G allele expression in cDNA was
56.0862.97%, significantly higher than observed in the genomic
DNA background (49.9660.34%; p=0.048; see Figure 3). Other
SNPs were either not significant or not consistent with adipose/
skeletal muscle gene expression (data not shown).
Association of insulin sensitivity with ACACB cis
transcribed SNPs in the metabolic sample
SNP rs2075260, which showed the strongest association
between adipose ACACB expression for EAs and AAs in the
biopsy sample, together with rs2075259 and rs2075263, which
Table 1. Demographic and laboratory characteristics of study sample.
Sample Race n (M/F) Age BMI TG TC HDL-C SI
(yr) (kg/m
2) (mg/dl) (mg/dl) (mg/dl) (610
24 min
21[mU/ml]
21 )
Biopsy Sample EA 105 (41/64) 40.3611.2 28.965.91 1326123 183635 53.7618.3 3.7062.04
AA 46 (29/17) 43.569.25 30.066.33 109665 175640 51.4612.7 3.2961.85
Metabolic Sample EA (all) 417 (163/254) 38.3610.3 29.366.1 NA NA NA 5.8565.97
EA(AR) 293 (112/181) 37.669.85 29.866.0 NA NA NA 4.0863.0
EA(UT) 124 (51/73) 40.1611.1 27.865.9 NA NA NA 9.7068.75
AA 153(68/85) 39.269.4 30.666.3 NA NA NA 3.7063.55
Data expressed as mean6SD. EA, European American; AA, African American; AR, Arkansas; UT, Utah; M, male; F, female; NA, not available;
TG, triglyceride; TC, total cholesterol; HDL-C, HDL cholesterol; SI, insulin sensitivity.
doi:10.1371/journal.pone.0023860.t001
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evaluated non-diabetic subjects (40 EA and 22 AA) (20), were
further genotyped in the metabolic sample (416 EA and 153 AA).
Rs7135947 was also genotyped in this sample due to significant
association with adipose ACACB expression in AAs from the biopsy
study sample. The association results with insulin sensitivity are
shown in Table 3. Only rs2075260 was nominally associated with
insulin sensitivity in EAs after adjusting for age, sex, BMI, sibship,
and cohort (Utah or Arkansas) (p=0.04, additive model). Allele G,
associated with higher ACACB expression in the adipose biopsy
sample (Figure 2) and AEI (Figure 3), was also associated with
lower insulin sensitivity in EAs after appropriate adjustment
(Figure 4). No significant association of this SNP was seen in AAs
(additive p=0.71; Table 3).
Adipose ACACB gene expression correlates with BMI in
EA
Adipose ACACB messenger RNA expression level was negatively
associated with age and sex-adjusted BMI in EAs (r=20.35,
p=0.0002; Figure 5a), but not in AAs (Figure 5b). Significant
differences in BMI or SI were not found between EAs and AAs in
Figure 1. Linkage Disequilibrium (LD) plot of studied ACACB SNPs. 1a: Linkage Disequilibrium (LD) plot of studied ACACB SNPs in European
Americans. 1b. Linkage Disequilibrium (LD) plot of studied ACACB SNPs in African Americans.
doi:10.1371/journal.pone.0023860.g001
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No. SNP ID
allele
1/2 Freq 1
11_
exp
11_
SE
11_
N
12_
exp
12_
SE
12_
N
22_
exp
22_
SE
22_
N
p_
add
p_
dom
p_
rec Ethniciity
p_
add_c Tissue
1 rs2878960 C/T 0.34434 1.81 0.31 10 1.73 0.13 53 1.68 0.15 43 0.71 0.78 0.74 EA 0.33 adipose
1 rs2878960 C/T 0.680851 2.34 0.22 21 2.14 0.21 22 1.62 0.51 4 0.22 0.26 0.37 AA adipose
2 rs4766516 A/G 0.212264 1.65 0.69 2 1.76 0.15 41 1.69 0.12 63 0.77 0.73 0.93 EA 0.9 adipose
2 rs4766516 A/G 0.053191 1.78 0.46 5 2.23 0.16 42 0.37 0.37 NA AA adipose
3 rs11065772 C/T 0.852381 1.73 0.11 77 1.63 0.19 25 2.18 0.57 3 0.94 0.42 0.83 EA 0.2 adipose
3 rs11065772 C/T 0.478261 1.93 0.29 12 2.08 0.23 20 2.59 0.27 14 0.10 0.09 0.30 AA adipose
4 rs2300455 C/T 0.783019 1.62 0.12 62 1.86 0.15 42 1.63 0.68 2 0.30 0.93 0.25 EA 0.37 adipose
4 rs2300455 C/T 0.989362 2.19 0.15 46 1.7 1 0.64 NA 0.64 AA adipose
5 rs7135947 C/T 0.45283 1.9 0.21 22 1.7 0.13 52 1.63 0.17 32 0.34 0.55 0.33 EA 0.05 adipose
5 rs7135947 C/T 0.691489 2.48 0.2 23 1.95 0.22 19 1.72 0.45 5 0.04 0.28 0.045 AA adipose
6 rs2268388 C/T 0.834951 1.76 0.12 72 1.6 0.19 28 1.83 0.57 3 0.65 0.84 0.55 EA 0.1 adipose
6 rs2268388 C/T 0.818182 2.43 0.18 30 1.75 0.29 12 1.61 0.74 2 0.04 0.47 0.03 AA adipose
7 rs2241220 C/T 0.84434 1.83 0.11 74 1.47 0.17 31 1.07 1 0.06 0.49 0.07 EA 0.16 adipose
7 rs2241220 C/T 0.695652 2.17 0.22 23 2.29 0.25 18 2.08 0.48 5 0.97 0.79 0.83 AA adipose
8 rs2075259 A/G 0.203883 3.91 0.67 2 1.7 0.15 38 1.65 0.12 63 0.10 0.39 0.0009 EA 0.03 adipose
8 rs2075259 A/G 0.423913 2.28 0.31 10 2.54 0.22 19 1.8 0.23 17 0.13 0.03 0.78 AA adipose
9 rs3742023 A/G 0.379808 1.74 0.26 14 1.66 0.14 51 1.79 0.16 39 0.71 0.57 0.95 EA 0.08 adipose
9 rs3742023 A/G 0.155556 1.57 0.66 2 1.39 0.29 10 2.47 0.16 33 0.003 0.0007 0.40 AA adipose
10 rs2075260 A/G 0.806604 1.67 0.11 67 1.67 0.15 37 3.93 0.66 2 0.17 0.0007 0.57 EA 0.02 adipose
10 rs2075260 A/G 0.659574 2.04 0.2 23 1.98 0.25 16 3.01 0.35 8 0.06 0.01 0.34 AA adipose
11 rs2075263 C/T 0.193396 3.93 0.66 2 1.66 0.15 37 1.68 0.11 67 0.22 0.67 0.0007 EA 0.05 adipose
11 rs2075263 C/T 0.212766 3.11 0.61 3 2.34 0.27 14 2.02 0.18 30 0.08 0.15 0.12 AA adipose
1 rs2878960 C/T 0.34434 0.74 0.1 10 0.88 0.05 53 0.82 0.05 43 0.90 0.56 0.26 EA 0.6 muscle
1 rs2878960 C/T 0.680851 0.97 0.09 21 0.86 0.09 22 0.73 0.2 4 0.22 0.40 0.28 AA muscle
2 rs4766516 A/G 0.212264 0.83 0.18 2 0.82 0.05 41 0.85 0.04 63 0.67 0.64 0.94 EA 0.84 muscle
2 rs4766516 A/G 0.053191 0.88 0.19 5 0.9 0.06 42 0.92 0.92 NA AA muscle
3 rs11065772 C/T 0.852381 0.86 0.04 77 0.75 0.07 25 0.97 0.21 3 0.42 0.53 0.25 EA 0.57 muscle
3 rs11065772 C/T 0.478261 0.79 0.12 12 1.02 0.09 20 0.81 0.11 14 0.97 0.35 0.30 AA muscle
4 rs2300455 C/T 0.783019 0.84 0.04 62 0.84 0.05 42 0.83 0.18 2 0.91 0.94 0.91 EA 0.81 muscle
4 rs2300455 C/T 0.989362 0.91 0.06 46 0.5 1 0.32 NA 0.32 AA muscle
5 rs7135947 C/T 0.45283 0.82 0.07 22 0.84 0.05 52 0.86 0.06 32 0.71 0.78 0.73 EA 0.87 muscle
5 rs7135947 C/T 0.691489 0.96 0.08 23 0.84 0.09 19 0.83 0.2 5 0.32 0.69 0.29 AA muscle
6 rs2268388 C/T 0.834951 0.86 0.04 72 0.81 0.07 28 0.92 0.18 3 0.76 0.71 0.61 EA 0.59 muscle
6 rs2268388 C/T 0.818182 0.95 0.08 30 0.85 0.12 12 0.69 0.31 2 0.34 0.50 0.40 AA muscle
7 rs2241220 C/T 0.84434 0.87 0.04 74 0.76 0.06 31 0.7 1 0.09 0.69 0.09 EA 0.55 muscle
7 rs2241220 C/T 0.695652 0.84 0.09 23 0.93 0.1 18 1.07 0.19 5 0.25 0.33 0.33 AA muscle
8 rs2075259 A/G 0.203883 0.83 0.25 2 0.82 0.05 38 0.85 0.04 63 0.74 0.73 0.96 EA 0.60 muscle
8 rs2075259 A/G 0.423913 0.82 0.13 10 0.93 0.09 19 0.92 0.1 17 0.57 0.82 0.45 AA muscle
9 rs3742023 A/G 0.379808 0.91 0.09 14 0.81 0.05 51 0.86 0.05 39 0.90 0.68 0.40 EA 0.70 muscle
9 rs3742023 A/G 0.155556 0.67 0.26 2 1.07 0.12 10 0.84 0.06 33 0.50 0.22 0.43 AA muscle
10 rs2075260 A/G 0.806604 0.86 0.04 67 0.81 0.06 37 0.84 0.26 2 0.52 0.99 0.49 EA 0.42 muscle
10 rs2075260 A/G 0.659574 0.83 0.08 23 0.81 0.09 16 1.27 0.14 8 0.03 0.003 0.30 AA muscle
11 rs2075263 C/T 0.193396 0.84 0.26 2 0.82 0.06 37 0.85 0.04 67 0.64 0.62 0.99 EA 0.51 muscle
11 rs2075263 C/T 0.212766 1.4 0.24 3 0.92 0.1 14 0.84 0.07 30 0.07 0.22 0.03 AA muscle
EA, European American; AA, African American. P values were adjusted by age, sex, BMI.
p_add, p value under dominant model; p_dom, p value under dominant model; p_rec, p value under recessive model; p_add_c, p value of combining EA and AA by
additional adjustment of race.
11_exp, 12_exp, 22_exp: ACACB relative expression levels in subjects with genotype 11, 12, and 22 respectively. Freq1: Frequency of allele 1; SE: standard error; N:
number of subjects.
doi:10.1371/journal.pone.0023860.t002
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was significantly lower in EAs than AAs in the biopsy sample
(Table 4).
Association of BMI, triglycerides (TG), total cholesterol
(TC), and HDL cholesterol (HDL-C) with ACACB cis
transcribed SNPs in the metabolic sample
No significant associations were identified with BMI, TG, TC
or HDL-C for the selected SNPs in the metabolic sample. SNP
rs2075260 showed the lowest p-values for association with BMI in
EAs and AAs (dominant p=0.19 and 0.10, respectively; Table
S1); however, significant association was not observed in the
combined EA and AA sample. No association was identified with
TG, TC, and HDL-C (data not shown).
Discussion
ACACB is a key rate limiting enzyme in mitochondrial fatty acid
oxidation. In this study, we found that the ACACB transcribed SNP
rs2075260 was associated with adipose tissue ACACB gene
expression in EAs and AAs and with insulin sensitivity in EAs;
the allele associated with lower gene expression was also associated
with higher insulin sensitivity. This is consistent with the mouse
model, which demonstrated that inhibition of Acacb improved
insulin sensitivity [3]. These data suggest that ACACB cis-acting
SNPs may regulate gene expression in humans, potentially altering
insulin sensitivity independent of BMI. Although the association of
rs2075260 with insulin sensitivity was not statistically significant in
the AA sample, the effect of this allele was similar in magnitude
and in the same direction as that observed in EAs. This result is
similar to that seen in an independent German Sorb population
sample whose LD pattern was similar to HapMap CEU with the
association between rs2075263 (C/T) and homeostasis model
assessment of insulin resistance (HOMA-IR; p=0.22, beta=0.06,
n=793) (personal communication: Stumvoll M, 2011) [21], as well
as in Diabetes Genetics Initiative (DGI) for HOMA-IR (p=0.03,
beta=0.11, n=1393), where the meta-p value of these two
cohorts reached 0.01 and 0.02 for Stouffer and Fisher’s methods
respectively with minor allele C indicating lower insulin sensitivity,
consistent with rs2075260 in Table 3 where minor allele G
represented lower insulin sensitivity in the AR and UT Caucasian
metabolic sample . Our inability to detect association at this locus
in AAs may reflect low statistical power in this small sample.
Concerns about multiple testing are relevant in genetic studies.
The number of SNPs to account for in this study is impacted by
the fact that rs2075259, rs2075260, and rs2075263 are in high
genotypic concordance in Caucasians. Given this, we presented
the raw p values without adjustment for multiple comparisons.
The non-synonymous SNP rs2075260 (G/A) encodes an
amino acid substitution Val2141Ile [NM_001093]. We are
unable to predict ACACB protein structural changes caused by
this amino acid substitution (http://snpeffect.vib.be/snp_main.
php?id=34162381). We scanned this SNP using MatInspector
(http://www.genomatix.de ) and TFSEARCH (http://www.
cbrc.jp/ research/db/TFSEARCH.html) and have not identified
potential anchoring loci for a transcription factor binding site at
rs2075260. Therefore, we are unable to determine whether this
SNP is a functional variant. However, rs2075259 (G/A), in high
genotypic concordance with rs2075260, forms activating protein
(AP1)/ v-maf musculoaponeurotic fibrosarcoma oncogene ho-
molog (MAF) anchoring sites for allele G (matrix similari-
ty=0.96-0.98), while allele A abolished these potential binding
sites. As we demonstrated, the G allele of rs2075259 is associated
with lower ACACB gene expression in adipose tissue (Table 2).
AP1/MAF may act as a suppressor, or impact other repressors, of
gene expression [22,23]. This is supported by the strong negative
correlation between messenger level of ACACB and MAF/AP1S2
(AP1 subunit 2) in our adipose gene global expression study in
non-diabetic subjects (unpublished data).
Figure 2. Adipose ACACB expression vs. rs2075260 in European Americans (EA) and African Americans (AA). Data are presented as
least squares mean6SE after controlling age, sex, and BMI. * The ends of the error bar are the only two data points of ACACB expression values
(adjusted for age, sex, and BMI) for this genotypic group. P values were adjusted for age, sex, and BMI. Fisher and Stouffer’s methods were used for
meta-analysis.
doi:10.1371/journal.pone.0023860.g002
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(Table S1). However, adipose ACACB expression was negatively
associated with age and sex-adjusted BMI in EAs (Figure 5a). This
correlation cannot be explained by the known regulatory function
of ACACB on body weight and insulin sensitivity in the mouse
model [2,3,4]. We suspect that BMI may regulate adipose ACACB
expression in EAs. Although this cross-sectional study cannot
provide direct evidence, this hypothesis is supported by our
observation that HepG2 cell ACACB expression was down-
regulated after treatment with 1 mM palmitate [13]. It is
conceivable that nutritional stress (e.g. diet-indued obesity and
free fatty acid exposure) regulates ACACB expression. Down
regulation of Acacb was observed in visceral fat tissue in rats fed a
high-fat diet, while Juniperus chinensis extract significantly reduced
this effect (14). AMPK (AMP activated protein kinase) may be the
link between ACACB gene expression and nutritional status [24].
ACACB activity [25] can be directly inhibited by AMPK. This
may constitute a physiologic link between higher BMI and lower
ACACB gene expression and supports the metabolic adaptation
model proposed by Weyer et al based on energy expenditure, fat
oxidation, and body weight regulation in Pima Indians [26]. The
lack of association between adipose ACACB gene expression and
BMI in AAs may be due to the smaller sample size or imprecision
of BMI as a measure of adiposity. Alternatively, AAs may be less
sensitive to nutritional stress in terms of regulating adipose ACACB
expression. Adipose ACACB expression levels are significantly
higher in AAs than EAs (Table 4). However, BMI and insulin
sensitivity were nearly equivalent in EAs and AAs in the biopsy
study sample (Table 4). This finding may reflect racial differences
in ACACB expression in response to similar body fat. Different
genetic or environmental factors may affect ACACB expression
between EAs and AAs.
ACACB variants have not been shown to be associated with BMI
or diabetes using GWAS. However, functional variants (e.g.
transcribed SNPs) may still regulate gene expression and impact
insulin sensitivity. Our biopsy sample was modest and generated
Figure 3. Allelic Expression of G of rs2075260 in both genomic
and cDNAs of Utah EA lymphoblast cell lines (n=18).
doi:10.1371/journal.pone.0023860.g003
Table 3. Association between selected transcribed SNPs and insulin sensitivity (SI) in the metabolic sample.
SNP Allele (1/2) Race SI vs.Genotype/n genetic power* P_add P_dom P_rec P_add_comb
CC CT TT
EA 6.3760.56 6.7960.37 7.1660.79 0.66 0.72 0.76
rs7135947 C/T n=416 81 217 118 0.99 0.71
AA 3.2860.27 4.5860.48 2.5560.36 0.92 0.10 0.36
n=153 73 64 16 0.60
AA AG GG
EA 6.3960.72 6.6960.46 6.9460.45 0.83 1.00 0.33
rs2075259 A/G n=411 17 148 246 0.99 0.75
AA 3.2360.42 3.6560.32 3.9360.44 0.60 0.74 0.52
n=149 14 67 71 0.58
AA AG GG
EA 7.0560.44 6.5060.47 5.8760.51 0.04 0.87 0.046
rs2075260 A/G n=415 257 140 18 0.99 0.07
AA 3.8160.38 3.7160.36 3.4860.38 0.71 0.25 0.98
n=152 79 61 12 0.59
CC CT TT
EA 5.6260.66 6.5960.47 6.9960.43 0.58 0.57 0.94
rs2075263 C/T n=416 12 134 270 0.99 0.68
AA 3.9060.58 3.7560.36 3.7360.36 0.41 0.61 0.20
n=152 7 59 86 0.59
EA European American; AA African American.
Data are presented as least squares mean6SE, after controlling for age, sex, and BMI.
Location (Arkansas/Utah) is additionally adjusted for in EA.
P_add reflects p-value for the additive model; P_dom reflects p-value for the dominant model; P_rec reflects p-value for recessive model.
P_add_comb is additionally adjusted for race when EA and AA are combined for analysis.
*Genetic power was estimated to detect 10% of the variation in insulin sensitivity and other metabolic traits in the metabolic sample(assuming a type 1 error
rate=0.0005).
doi:10.1371/journal.pone.0023860.t003
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detect 20% of the variation in gene expression levels (assuming a
type 1 error rate=0.0005). Larger populations will be necessary to
replicate these results. The lack of association of ACACB variants
with BMI/diabetes may also reflect the masking effect of
gene*gene and gene*environment interactions. A recent gene*en-
vironment interaction study of ACACB variants and metabolism
suggested that uncovered causative variants may have been
overlooked in published GWAS [16]. Acacb knock-out mice were
only protected from obesity and diabetes when fed high fat/high-
carbohydrate diets; when fed normal chow, significant differences
in body weight were not observed [3].
Two independent groups reported that Acacb knock-out mice
have similar body weights as wild type mice [27,28]. Molecular
explanations for the phenotypic differences observed between
Olson’s model of Acacb deletion and the original model (prone to
resistant to obesity, diabetes and insulin resistance) published by
Abu-Elheiga et al. [2] are not clear. Although the Acacb biotin-
binding site was deleted in both models, different targeting
strategies were employed. The targeting strategy employed in the
original study replaced only the exon containing the biotin binding
motif [2]. RNA splicing across the targeting cassette might leave
the mRNA in frame, resulting in a mutated but otherwise intact
protein lacking a catalytic domain. If produced, such a protein
might potentially have ‘‘dominant negative’’ activity toward
ACACA [27]. This may be supported by the effects of soraphen,
an inhibitor of both ACACA and ACACB, improving peripheral
insulin sensitivity in mice fed high-fat diets [29]. It suggests that
lower ACACB expression alone may be insufficient to improve
insulin sensitivity. As in the present study, association between
rs2075260 and SI was weaker compared to the association with
gene expression. It is noteworthy that this result was based on
transcript messenger level only, as protein level and enzyme
activity data are not available yet. Limitations of this study
included the small sample of AA subjects, lack of longitudinal
follow-up data and lack of dietary intervention. These factors limit
interpretation of gene expression effects. We also lack quantifiable
life-style data to use as covariates in our database. Free fatty acid
(FFA) levels fluctuate even with fasting. Healthy non-diabetic, non-
drug or tobacco using subjects should be recruited on balanced
diets for three days, with blood samples drawn after an overnight
fast. We are not confident that our blood samples meet these
criteria. Therefore, we elected not to measure FFAs in our sample.
We were unable to test the effects of specific ACACB inhibitors on
human insulin sensitivity. Finally, due to the large size of the
ACACB gene (Ensembl transcript ID ENST00000338432: 55
exons spanning 150 kb), where 142 SNPs were available in
HapMap database (NCBI builder 36), we prioritized the effect of
transcribed SNPs on gene expression. The most significant SNP
for adipose ACACB expression in the biopsy sample (rs2075260)
was in high genotypic concordance with rs2075259 and
rs2075263, which rank among the top SNPs in skeletal muscle
eQTL mapping [20]. However, rs2075260 was not associated with
skeletal muscle ACACB expression in the biopsy sample. This
observation is not uncommon in terms of eQTLs in different cell
types [30]. This could also result from different transcript forms
presented across different cell types or variation in participant
characteristics in the two study samples. In addition, the ACACB
probe (Agilent expression array) applied in the eQTL mapping
[20] was located at the 39 UTR of the ACACB gene, while the
expression primer set (for RT-PCR) used in the current study was
designed across exon 13 and 14, in an attempt to cover all of the
reported transcripts. Transcribed SNPs are a logical source for
testing AEI as a complementary prioritization method for gene
expression based on genotype. We chose lymphoblast cell lines for
AEI studies instead of adipose tissue due to mixed sources of
adipose RNA, as well as the restricted amount of tissue RNA
available. It can be argued that lymphoblast cell lines are not the
most relevant cell types to evaluate insulin action. However, our
prior study revealed that lymphoblast cell lines provided
confirmatory evidence for eQTLs in insulin-response tissues [31].
Our data suggest that the common transcribed SNP rs2075260
(A/G) in the coding region of the ACACB gene is associated with
adipose tissue ACACB messenger RNA expression in EAs and AAs.
The G allele, representing higher levels of gene expression, is also
associated with lower insulin sensitivity in EAs. Body fat,
represented by BMI, may serve as a ‘‘negative feed-back’’ signal
down-regulating ACACB expression in adipose tissue, possibly as a
mechanism of metabolic adaptation. Longitudinal intervention
studies will assist in interpreting whether high ACACB expression is
a risk factor for obesity and type 2 diabetes. Gene*gene interaction
studies in larger cohorts will be helpful to identify any undetected
diabetes or obesity genes that interact with ACACB. Analysis of
alternative splicing of ACACB in adipose tissue and skeletal muscle
may be helpful to address tissue-specific transcripts and regulatory
SNPs involved in gene expression.
Materials and Methods
Subjects and phenotypes
The ‘‘biopsy sample’’ consisted of 105 EAs and 46 AAs from
Little Rock, Arkansas who lacked diabetes based on ADA
diagnostic criteria 2010 [32]. All participants underwent a
screening visit during which height, weight, fasting blood lipids,
and blood insulin and glucose concentrations (fasting, 30, 60 and
120 minutes after a standard 75-g oral glucose load) were
measured, and adipose and skeletal muscle biopsies were
performed using a Bergstrom needle under local (lidocaine)
anesthesia at University of Arkansas for Medical Sciences
(UAMS), Little Rock, Arkansas. Biopsy samples were immediately
rinsed in normal saline, cut, and snap frozen in liquid nitrogen.
Premenopausal women were studied in the follicular phase of the
menstrual cycle.
The ‘‘metabolic sample’’ consisted of 440 non-diabetic EAs (417
with measures of insulin sensitivity) and 163 non-diabetic AAs (153
with measures of insulin sensitivity). AAs were recruited in
Arkansas, whereas 293 EAs were recruited from Arkansas and
124 were siblings from 62 nuclear families of Northern European
descent ascertained in Utah. Subjects in the previously described
‘‘biopsy sample’’ were a subset of the Arkansas ‘‘metabolic
sample’’. An insulin-modified (0.04 U/kg), frequently sampled
Figure 4. Insulin sensitivity by genotype of rs2075260 in
European Americans. Data are presented as least squares mean6SE
after controlling age, sex, BMI, cohort, and sibship. Additive P-value was
adjusted for age, sex, BMI, cohort, and sibship (GEE model).
doi:10.1371/journal.pone.0023860.g004
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reported [33]. Insulin sensitivity (SI) was calculated from the
FSIGT using either the MinMod (Utah sample) or MinMod
Millenium (Arkansas Sample) programs [34,35]. These programs
use the same algorithms and provide nearly identical estimates of
SI.
Figure 5. Adipose ACACB expression vs. adjusted BMI. Figure 5a Adipose ACACB expression vs. adjusted BMI in EA. Figure 5b Adipose ACACB
expression vs. adjusted BMI in AA.
doi:10.1371/journal.pone.0023860.g005
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approved by either the Institutional Review Board of the
University of Utah Health Sciences Center or UAMS. Informa-
tion from these subjects was de-identified and samples transferred
to the Wake Forest University School of Medicine (WFUSM). This
study was approved by the WFUSM Institutional Review Board.
Laboratory measurements
Insulin levels were measured using an immunochemilumino-
metric assay (Molecular Light Technology, Wales, UK) and
plasma glucose by a glucose oxidase assay. Standard clinical assays
(lipids, glucose) were performed at LabCorp (Burlington, NC).
Genotyping
Eight common transcribed ACACB SNPs were genotyped in the
biopsy sample (rs2878960, rs4766516, rs11065772, rs2300455,
rs7135947, rs2241220, rs3742023, rs2075260), all with minor
allele frequencies .0.05 in Caucasians and Yoruba Africans based
on HapMap data (http://hapmap.ncbi.nlm.nih.gov/). Addition-
ally, rs2268388 (significantly associated with diabetic nephropathy)
[6,17] and rs2075259/rs2075263 (two top SNPs for ACACB
expression quantitative trait loci [eQTL] in skeletal muscle) [20]
were genotyped. Genotyping of the biopsy sample was performed
on a PSQ 96 Pyrosequencer (Biotage, Uppsala, Sweden).
Additional genotyping in metabolic sample participants was
performed by pyrosequencing or the ABI TaqMan assay (Applied
Biosystems, Foster City, CA). Genotype distributions for all
variants met Hardy-Weinberg expectations (p.0.01). The overall
genotype call rate was above 98%. Sixty-nine duplicated QC
samples were randomly distributed across genotyping plates of the
metabolic sample to assure 100% reproducibility. For the biopsy
sample, in addition to the fact that pyrosequencing is a highly
reliable genotyping method which visualizes and quantifies both
alleles of target SNPs, AEI requires genotyping of both genomic
and cDNAs, which virtually serve as duplicates to assure accuracy.
Linkage disequilibrium plots (D9 and r
2) were generated using
the HaploView program (http://www.broadinstitute.org/ haplo-
view).
Gene expression
Total RNA was isolated from subcutaneous adipose tissue using
the RNAeasy Lipid Tissue Mini Kit (QIAGEN, Valencia, CA) and
from skeletal muscle using the Ultraspec RNA kit (Biotecx
Laboratories, Houston, TX). The quantity and quality of isolated
RNA were determined by ultraviolet spectrophotometry and
electrophoresis, respectively, using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA), and 1 mg was reverse
transcribed using random hexamer primers with Qiagen reverse
transcribed reagents (QIAGEN, Valencia, CA). All RNA samples
from a single study population and tissue were reverse transcribed
using the same kit on the same day. The standard curves were
generated using pooled RNA from assayed samples. Primers were
designed to capture most known splice variants where the
amplicon spanned an intron. ACACB expression was measured
by real time PCR (SybrGreen) on an ABI 7500-Fast Real time-
PCR system (Applied Biosystems, Foster City, CA) using 18S
ribosomal RNA as a normalization standard. Primer sequences
were as follows: 18S forward: ATCAACTTTCGATGG TAG-
TCG, 18S reverse: TCCTTGGATGTGGTAGCCG, ACACB–
Forward: GGGCTCCTGCTCTCCTACA, ACACB – Reverse:
CGTTCTCCTTCTCAAACACACA [36].
Allelic expression imbalance (AEI)
Transformed lymphocytes were cultured from an independent
sample of 95 unrelated HapMap Utah Caucasians (EAs) as
reported [30]. Total RNA was extracted using the RNEasy mini
kit (QIAGEN, Valancia, CA), quantity and quality was assessed on
an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Santa
Clara, CA). Unequal expression of ACACB alleles was sought as
evidence for cis acting regulatory variants by comparing peak
heights in individuals heterozygous for the synonymous coding
SNPs rs2878960, rs4766516, rs2300455, rs7135947, rs2241220,
and rs2075260 [37]. Rs11065772 and rs3742023 failed in assay
design. Briefly, total RNA was reverse transcribed using random
hexamers. Allelic specific quantitation of both cDNA and genomic
DNA samples was determined using the same assay for
pyrosequencing on a PSQ 96 Pyrosequencer (Biotage, Uppsala,
Sweden) with peak height quantified using Allele Quantification
software (Biotage, Uppsala, Sweden).
Statistical analysis
SI was estimated from the insulin and glucose data using either
the MinMod (Utah sample) or MinMod Millenium (Arkansas
sample) programs. Gene expression levels were normalized to 18S
RNA and the ratio was used in\all calculations. Statistical analyses
were performed using the SAS 9.1 software of the SAS Institute
(Cary, NC). Correlations between ACACB expression and BMI or
SI were assessed using a general linear model after controlling
potential confounders (age, race, sex, BMI). To approximate
normality, the logarithm of ACACB expression was used in all
analyses. Allelic specific expression was assessed by comparing the
percentage of normalized genomic and cDNA expression on
observed alleles using the method of Fogarty et al [38]. For the
biopsy samples, a generalized linear model (GENMOD) was used
to assess the association between genotype and ACACB gene
Table 4. Comparison of ACACB expression, Si, and BMI
between EAs and AAs in the biopsy. Sample.
EA AA P value Adjustment
(n=105) (n=46)
Adipose ACACB
expression
1.6860.10 2.3360.15 0.0004 age, sex, BMI
Adipose ACACB
expression
1.7660.10 2.3760.17 0.002 age, sex, SI
SM ACACB
expression
0.8360.03 0.9360.06 0.15 age, sex
SM ACACB
expression
0.8360.03 0.9360.06 0.15 age, sex, BMI
SM ACACB
expression
0.8060.04 0.9060.06 0.18 age, sex, SI
SI (610
24
min
21[mU/ml]
21 )
3.6560.19 3.6060.30 0.88 age, gender,
BMI
BMI (kg/m
2) 28.160.54 29.660.86 0.15 age, gender
Data are least squares mean6SE. The controlled covariates are listed in the
adjustment column.
SM: skeletal muscle; EA: European American; AA: African American.
doi:10.1371/journal.pone.0023860.t004
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sex were not obvious confounders (Table S2). For analysis under
an additive model, homozygotes for the allele (1/1), heterozygotes
(1/2), and homozygotes for the allele (2/2) were coded to a
continuous variable (0, 1, and 2). The dominant model was
defined as contrasting genotypic groups 1/1+1/2 vs. 2/2. The
recessive model was defined as contrasting genotypic groups 1/1
vs. 1/2+2/2. The generalized estimating equations (GEE)
procedure was used to account for sibships in the metabolic
sample in addition to age, sex, BMI, and cohort, since Utah
subjects were family-based. We analyzed each SNP using the same
genetic model for all analyses, irrespective of the study sample. A
meta-analysis was performed using Stouffer [39] and Fisher’s
method [40]. P-values ,0.05 were considered to represent a
nominal level of statistical significance.
Supporting Information
Figure S1 Linkage Disequilibrium (LD) plot of studied
ACACB SNPs in HapMap. S1a: Linkage Disequilibrium (LD)
plot of studied ACACB SNPs in HapMap Caucasians. S1b.
Linkage Disequilibrium (LD) plot of studied ACACB SNPs Yoruba
Africans.
(TIF)
Figure S2 Adjusted ACACB expression by sum of eQTL-
increasing alleles in adipose. Adjusted ACACB expression
levels were controlled for age, sex, BMI, and ethnicity. eQTL-
increasing alleles: G for rs2075260; C for 7135947. P values were
obtained under general linear model (GLM). EA: European
American; AA: African American; All: EA and AA combined.
(TIF)
Table S1 Association between selected transcribed SNPs and
BMI in the metabolic sample. Data are least squares mean6SE,
after controlling age and sex. Cohort location (Arkansas/Utah) is
additionally adjusted for in EA.
(XLS)
Table S2 Summary of Type III testing for age and sex as
individual coefficients of ACACB expression in the biopsy sample.
EA: European American; AA: African American; DF: degree of
freedom.
(XLS)
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